Recent advances in schistosomiasis

Olds, G R; Dasarathy, Srinivasan

doi:10.1007/s11908-001-0060-1

Cited by 11 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The muticellular parasite S. mansoni is responsible for schistosomiasis, affecting more than 200 million people in > 70 countries (115)(116). The parasites can survive for up to decades in the human host, as it has a unique set of antioxidant enzymes that continuously degrade the ROS produced by the host's innate immune response.…”

Section: Redox-active Drugs Against Multicellular Parasitesmentioning

confidence: 99%

Redox-Active Antiparasitic Drugs

Pal

Bandyopadhyay

2012

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

show abstract

Section: Redox-active Drugs Against Multicellular Parasitesmentioning

confidence: 99%

Redox-Active Antiparasitic Drugs

Pal

Bandyopadhyay

2012

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

show abstract

“…With the lowering costs of praziquantel, the cost differential is now negligible. This has led to discontinuation of drug distribution in several endemic countries (Olds & Dasarathy 2000).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa

Silva

Thiengo²,

Conceição

et al. 2005

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Schistosoma haematobium is present in about 53 African countries and in the Middle East, with the helminth showing high endemicity in these regions (CEGET-CNRSAtlas-WHO/1987, home page-WHO). Urinary schistosomiasis is an infectious disease of marked epidemiological importance for both natives and tourists exposed to the helminth in endemic regions.Treatment of urinary schistosomiasis has shown great advances with the introduction of praziquantel into the therapeutic arsenal (Bormann et al. 2001, De Clerq et al. 2002. Advantages of this drug include its easy administration (40 mg/kg body weight, a single dose by the oral route), low toxicity, and low intensity of side effects (McMahon 1983, Pugh & Teesdale 1983, Kahama et al. 1999, Rey 2001. These important factors have contributed to the tolerance with and easy application of individualized and mass treatments (Stephenson et al. 1989, King et al. 1992. Nevertheless, failure of praziquantel treatment of various proportions has been reported (Herwaldt et al. 1995, Liang et al. 2000. So, it is necessary to be sure about the + Corresponding author. E-mail: silva.iran@ig.com.br PATIENTS AND METHODSThree 24-h urine samples were collected from 26 patients at minimum intervals of one week. The patients were Brazilian military men who were part of the United Nation peace mission in Mozambique in 1994, age between 26 and 55 years old, median age of 29 years. The principal condition was the report of exposure in Licungo river and signals and symptoms affecting the genitourinary tract after exposure.Helminth eggs were recovered by spontaneous sedimentation and subsequent centrifugation of the urine sample. The total urine volume was transferred to glass chalices and left to stand for 24 h. After this period, 10 ml of the initial sediment was removed with a glass pipette held close to the bottom of the chalice and centrifuged at 3500 r.p.m. for 5 min. One-hundred microliters of the centrifuged material was removed with a glass pipette held close to the bottom of the tube, mounted on a slide, coverslipped, and observed under a microscope at magnifications of 100× and 400×. For endoscopic examination, an Olympus model 19 CH cystoscope with a 30 o eyepiece was used. 446 446 446 446 Schistosoma haematobium in Brazilians • • • • • Iran Mendonça da Silva et al.After the positive diagnosis, the patients were treated with 40 mg/kg body weight praziquantel administered in a single dose. Three other 24-h urine exams were repeated at 7-day intervals by the same technique, after a minimum period of 21 days after treatment. Treatment was repeated under medical supervision to ensure the correct use of the drug. In the case of suspicion of lesions, all individuals were submitted to cystoscopy followed by biopsy and histopathological examination at 6-month intervals, after each treatment or retreatment, under the same conditions as used for the initial diagnosis. The urine examination, with the same technique, was repeated after each cistoscopy.In the case of evidence of vesical involveme...

show abstract

“…In the case of a S. mansoni and S. haematobium mixed infection, combined therapy with oxamniquine and metrifonate (Table 5, entry 21) seems efficient (Olds and Dasarathy 2000). Therefore, oxamniquine may be used as an alternative to praziquantel, as it stands, or may be further modified under drug-design studies to be active against other schistosome species (Kayser et al 2003a,b;Utzinger et al 2003;Cioli 2000).…”

Section: Combination Of Drugs In Different Chemotherapy Regimensmentioning

confidence: 99%

Schistosomiasis—a century searching for chemotherapeutic drugs

2006

View full text Add to dashboard Cite

Schistosomiasis affects 200 million individuals in underdeveloped and developing regions and is a growing concern for travelers worldwide. There has been evidence of resistance to the praziquantel-based therapy and reports of acute-disease manifestation; therefore, other drugs affecting different stages of the schistosome parasites life cycle and alternative therapeutic regimens should be developed and become accessible. The present review results from a comprehensive search in the scientific literature for substances and compounds tested in the past centennial for schistosomiasis therapy. We gathered over 40 drugs providing information on therapeutic action in humans or animal model, toxicity, susceptible Schistosoma stages, species, etc. The drugs were grouped according to their known metabolic effects on the parasite, whether they are on membrane structure and function, carbohydrate metabolism, protein synthesis and function, or on nucleic acid metabolism. We discuss the current knowledge of drug-target interactions, their mechanism of action and possible therapy combinations. Furthermore, based in the literature and in our own experience with large-scale Schistosoma mansoni genome and transcriptome analyses, we put forward several recently described gene products that are promising target candidates for existing or new drugs.

show abstract

Recent advances in schistosomiasis

Cited by 11 publications

References 45 publications

Redox-Active Antiparasitic Drugs

Redox-Active Antiparasitic Drugs

Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa

Schistosomiasis—a century searching for chemotherapeutic drugs

Contact Info

Product

Resources

About